Liberate Bio gains licences for myeloid-specific CAR design patents [Yahoo! Finance]
Carisma Therapeutics, Inc. (CARM)
Company Research
Source: Yahoo! Finance
Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for myeloid cells, such as monocytes and macrophages. The licences sourced from Carisma Therapeutics and the University of Pennsylvania include methods and constructs specifically engineered for function within these immune cell populations. The designs complement Liberate Bio's lipid nanoparticle (LNP) delivery platform, which enables the selective programming of macrophages and monocytes in vivo. With both the optimised CAR-sequence intellectual property and its cell-selective LNP technology, Liberate Bio is now positioned to advance in vivo CAR-M therapies into clinical assessment. Liberate Bio's Raptor platform conducts direct screening of LNPs in non-human primates to discover delivery vehicles aimed at extrahepatic immune cells. The company has previously disclosed that its lead LNP resulted in more than 99% depletion of circulati
Show less
Read more
Impact Snapshot
Event Time:
CARM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CARM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CARM alerts
High impacting Carisma Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics